KDM1A and acute lymphoblastic leukemia: Moreover, LSD1 inhibition with GSK-LSD1 reduced globally the H3K4me2 mark in Zeb2Tg ETP-ALL, and in combination with Ruxolitinib (JAKi) reduced slightly the repressive mark H3K27me3 but without major changes in the active marks H3K27ac and H3K4me3/1.